Biocryst Pharmaceuticals Inc
BCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882796
No open-market purchases or sales by Biocryst Pharmaceuticals Inc insiders were filed in the last 90 days; 320 institutions reported holding it in 13F filings for Q2 2026, worth $2.61B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $1.96B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +18 vs. previous quarter
- 320
- 13F valueReported value at the end of Q2 2026
- $2.61B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $874.8M
- +94.1% year over year
- Net income, FY2025
- $263.9M
- No comparable prior period
- Free cash flow, FY2025
- $344.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $180.3M
- +13.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 27.6M
- Shares sold short
- Change
- +1.04M
- +3.9% vs. previous
- Days to cover
- 5.09
- At average daily volume
Superinvestors holding BCRX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding BCRX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Biocryst Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 (view filing) | May 18 | 1 day | McKee Amy EDirector | SSale | −11.2K | $8.97 | −$100.3K | −26.3%31.3K after | |
| May 15, 2026 (view filing) | May 13 | 2 days | Barnes Alane PChief Legal Officer | SSale | −62.5K | $9.54 | −$596.3K | −13.5%400.7K after | 10b5-1 |
| Mar 24, 2026 (view filing) | Mar 20 | 4 days | Heggie TheresaDirector | SSale | −49.9K | $10.11 | −$504.8K | −43.3%65.4K after | |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Barnes Alane PChief Legal Officer | SSale | −150.0K | $9.15 | −$1.37M | −27.2%400.7K after | 10b5-1 |
| Dec 23, 2025 (view filing) | Dec 22 | 1 day | Barnes Alane PChief Legal Officer | SSale | −21.8K | $7.65 | −$166.6K | −5.2%398.8K after | 10b5-1 |
| Dec 16, 2025 (view filing) | Dec 15 | 1 day | Barnes Alane PChief Legal Officer | SSale | −21.2K | $7.65 | −$162.3K | −6.3%315.7K after | 10b5-1 |
| Dec 3, 2025 (view filing) | Dec 1-3 | 2 days | Barnes Alane PChief Legal Officer | SSale | −161.7K | $7.20 | −$1.16M | −31.9%345.5K after | 3 lots10b5-1 |
| Nov 17, 2025 (view filing) | Nov 13 | 4 days | Sanders MachelleDirector | SSale | −9.60K | $7.14 | −$68.5K | −23.9%30.6K after | 10b5-1 |
| Aug 15, 2025 (view filing) | Aug 13 | 2 days | Heggie TheresaDirector | SSale | −70.0K | $8.51 | −$595.7K | −51.7%65.4K after | |
| Dec 16, 2024 (view filing) | Dec 13 | 3 days | Hutson Nancy JDirector | SSale | −7.00K | $7.54 | −$52.8K | −7.5%86.6K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 320 holdersThe largest institutional positions in Biocryst Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 23,893,036 | $238.9M | 0.00% | +1,242,048+5.5% | Added |
| Ra Capital Management, L.P. | 15,827,186 | $158.3M | 1.38% | 00.0% | Unchanged |
| State Street Corp | 15,191,098 | $151.9M | 0.00% | +2,982,738+24.4% | Added |
| Deerfield Management Company, L.P. (Series C) | 15,096,403 | $151.0M | 1.57% | +58,403+0.4% | Added |
| Vanguard Capital Management LLC | 11,364,236 | $113.6M | 0.00% | +228,474+2.1% | Added |
| Vanguard Portfolio Management LLC | 11,139,158 | $111.4M | 0.01% | −105,467−0.9% | Reduced |
| TCG Crossover Management, LLC | 11,020,968 | $110.2M | 2.65% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 10,308,888 | $103.1M | 1.60% | +2,874,855+38.7% | Added |
| Jupiter Topco LLC | 9,540,764 | $95.3M | 0.04% | +9,540,764 | New |
| Vestal Point Capital, LP | 8,300,000 | $83.0M | 1.94% | +1,275,000+18.1% | Added |
Holders of 5% or more of BCRX
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Biocryst Pharmaceuticals Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.40%17.5M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| Flynn James E | 13G/A | 6.81%14.3M shares | +1.01 ppfrom 5.80% | Sep 19, 20252 filings | Feb 12, 2026 | SEC |
| Ra Capital Management, L.P. | 13G/A | 6.20%15.8M shares | −1.10 ppfrom 7.30% | Nov 12, 20252 filings | Aug 14, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.16%13.0M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
Politician trades
All politician trades in BCRX2 members of Congress reported 5 trades in Biocryst Pharmaceuticals Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Sep 4, 2026 |  Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Dec 15, 2025 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Nov 11, 2023 |  Josh Gottheimer House · NJ | Buy | $1K-$15K |
| Oct 15, 2023 | Josh Gottheimer House · NJ | Sell | $1K-$15K |
| Sep 16, 2022 | Josh Gottheimer House · NJ | Buy | $1K-$15K |
House · CA · Sep 4, 2026
Buy$1K-$15K
House · CA · Dec 15, 2025
Buy$1K-$15K
House · NJ · Nov 11, 2023
Buy$1K-$15K
House · NJ · Oct 15, 2023
Sell$1K-$15K
House · NJ · Sep 16, 2022
Buy$1K-$15K